Zacks.com on MSN6h
Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate
Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...
Could Ozempic Help Treat Substance Use Disorder? This Expert Is Hopeful
More than 48 million Americans 12 years or older had a substance use disorder in 2022, yet only 24 percent received treatment ...
STAT11h
Pharmalittle: We’re reading about a Merck deal, GSK cancer drug data, and more
In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...
Weight-loss drugs replacing some surgeries, but doctors say they're 'not a miracle drug'
Researchers looked at the health records of 17 million Americans with obesity and determined that between 2022 and 2023, ...
Medscape17h
Semaglutide 2.4 mg Could Cut Medical Costs for Some
A manufacturer-funded study found a significant decrease in annual total medical costs in patients with overweight/obesity ...
Eli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free
Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...
San Francisco Examiner3d
California Residents Are Using GLP-1s at the 11th Lowest Rate in the Country
Medications such as semaglutide (branded as Ozempic and Wegovy ... these drugs have been shown to facilitate significant ...
Endocrinology Advisor7d
GLP-1 Drug Shortages: How Do They Affect Patients With Diabetes?
GLP-1 receptor agonists promote weight loss, which is a goal for many patients.” Despite the FDA approval of several GLP-1 ...
Le Lézard10d
Celebrating 25 Years of Sculptra®: New Data and Recent Approval in China Cements Galderma's Leadership in Regenerative Biostimulation
This month marks the 25th anniversary of the approval of Sculptra®, the first proven regenerative biostimulator with a unique poly-L-lactic acid (PLLA-SCAtm) formulation.1-5,10-16 Sculptra works with ...
STAT13d
Novo asks FDA to bar compounders from making Ozempic copies
Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug ... shortage by the FDA, which semaglutide has been ...
Seeking Alpha15d
Hims & Hers stock falls 14% after FDA changes semaglutide supply status (update)
Shares of Hims & Hers (NYSE:HIMS) fell 14% Wednesday following news that Novo Nordisk’s (NVO) weight-loss ... FDA’s drug shortage list for months. Both drugs are based on the compound semaglutide.